"Their vision and long-term dedication have enabled us to effectively address many of the key challenges facing the field and to emerge with one of the industry's most robust clinical-stage gene therapy pipelines; as well as exclusive rights to commercialize a proprietary manufacturing platform, supply from a world-class manufacturing facility and a founding team with a proven track record of executing safe and effective gene therapy trials for nearly two decades. October was an important month for Spark Therapeutics . The company is also advancing toward the clinic with gene therapy programs to address neurodegenerative diseases and additional hematologic disorders and other forms of inherited blindness. Spark Therapeutics, Inc. Feb 2020 - Dec 2020 11 months. Environmental, Social and Governance (ESG), HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. Spark Therapeutics is comprised of over 800 employees with its headquarters situated in Philadelphia, USA. This feature is in beta and may change with future updates. Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. Iowa City, Iowa, United States. Spark Therapeutics is an equal opportunity employer. How much funding has this organization raised over time? . All news about SPARK THERAPEUTICS INC. CombiGene's and Neurochase's preclinical study provides valuable information for the up.. GMP production of CG01 made available for preclinical studies planned to enable First i.. Description. Their latest funding was raised on May 27, 2014 from a Series B round. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. When typing in this field, a list of search results will appear and be automatically updated as you type. Notably, Spark has exclusive rights to commercialize CHOP's proprietary manufacturing technology and will use clinical . NGK 2625: 12 mm x 1.25 mm:. Active, Closed, Last funding round type (e.g. To learn more visit www.sparktx.com. Spark Therapeutics is actively using 64 technologies for its website, according to BuiltWith. Spark's most advanced clinical program is a Phase 3 study to address blindness caused by mutations in the RPE65 gene. Pfizer is a leader in hemophilia, developing the first recombinant Factor IX product," said Dr. Katherine High, a hematologist and co-founder, president and chief scientific officer of Spark. Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark Therapeutics is focused on the development of treatments for genetic diseases. Spark will be responsible for conducting all Phase 1/2 studies while Pfizer will assume responsibility for pivotal studies, any regulatory approvals and potential global commercialization of the product. Spark Therapeutics is a publicly traded company on NMS using the ticker symbol ONCE. Under the terms of the agreement, Spark will receive an upfront payment of $20 million and will be eligible for additional development and commercialization milestone payments of up to $260 million for multiple hemophilia B product candidates that may be developed under the collaboration. Associate Professor of Neurology. Fully Integrated Gene Therapy Company with Deep Clinical Pipeline Spun out of The Children's Hospital of Philadelphia. PHILADELPHIA, PA, USA I February 01, 2021 I Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic . . Search this spark plug cross reference with more than 90000 models . It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Spark will assume control over two gene therapy clinical trials: a Phase 3 study for inherited blindness caused by mutations of the RPE65 gene and a Phase 1/2 study for hemophilia B. "We are excited to announce our collaboration with Pfizer, as we believe it marks an important step towards bringing a potentially life-altering therapeutic to patients with hemophilia B," said Jeffrey D. Marrazzo, co-founder and chief executive officer of Spark. About. AAPL, FB, TWTR), Total amount raised across all funding rounds, Total number of lead investment firms and individual investors, Total number of investment firms and individual investors, Announced Date: Date that the Funding Round was publicly announced, Transaction Name: Auto-generated name of transaction (e.g. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical . and menstrual hygiene products to women experiencing homelessness . AAPL, FB, TWTR), Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Spark is a gene therapy leader seeking to transform the lives of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments. philadelphia, oct. 22, 2013 /prnewswire/ -- spark therapeutics, a new, fully integrated company developing gene-based medicines for a wide range of debilitating diseases, announced today it has. At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of . Leading gene therapy Company will partner with established market leader to develop a potential new treatment paradigm for hemophilia B. PHILADELPHIA, Dec. 8, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating genetic diseases, announced today that it has entered into a global collaboration with Pfizer Inc. for the development and potential commercialization of SPK-FIX, a development program advancing proprietary, bio-engineered adeno-associated virus (AAV) vectors for the potential treatment of hemophilia B. About Spark TherapeuticsSpark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark's current valuation leaves room for substantial upside in the following years. This study provides information about the sales and revenue during the historic and forecasted period of 2021 to 2030 High, M.D, a gene therapy pioneer who has served as the director of the CCMT since its inception. The organisation is a fully integrated, commercial company committed to discovering, developing and delivering gene therapies for genetic diseases, including inherited retinal disorders, haemophilia, lysosomal storage disorders and neurodegenerative diseases. Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginableuntil now. The open-label, randomized, controlled study builds on an earlier clinical study in which 12 patients with RPE65-related blindness demonstrated notable improvement in visual function, moving in some cases from being profoundly blind to being able to recognize faces and ambulate independently. After extensive research and analysis, Zippia's data science team found the following key financial metrics. Dec 08, 2014, 07:30 ET. Spark has entered into agreements with multiple academic institutions to assemble the technology, programs and capabilities needed to deliver its pioneering gene therapy products. PHILADELPHIA, Dec. 8, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating genetic diseases, announced today . In hemophilia B, the company's Phase 1/2 study is enrolling up to 15 subjects who will receive a one-time dose through an intravenous infusion of the gene responsible for expressing factor IX. The Company focuses on treating orphan diseases. "Filtering down to just Philadelphia proper does reveal that . To learn more, visitwww.sparktx.com. Trademark applications show the products and services that Spark Therapeutics is developing and marketing. Detailed information on company financials and operating reports can be found here: . The open-label, dose escalation study is designed to assess safety and effectiveness of gene therapy in inducing the body to create native factor IX, as measured in their blood. "The creation of Spark is the culmination of a decade-long commitment by CHOP and our founding team to drive the field of gene therapy forward during a time when many in the industry had moved away," said Jeffrey D. Marrazzo, co-founder, president and chief executive officer of Spark Therapeutics. View contacts for Spark Therapeutics to access new leads and connect with decision-makers. To learn more please visit the Spark website at www.sparktx.com/pipeline/hematologic-disorders. Spark Therapeutics uses 27 technology products and services including HTML5, Google Analytics, and jQuery, according to G2 Stack. The founding team includes scientists who have led the advancement of gene therapy . R&D in Biotech, Environmental and various industries (no marketing product yet) Tags Biotechnology, Healthcare Venture Deals, Healthcare IPO Companies managed Acquired/Merged Spark Therapeutics Headquarters 3737 Market Street Suite 1300 Philadelphia, PA 19104 US (888) 772-7560 info@sparktx.com Web Site N/A Milestones Related Companies Director, Neurology Residency Program. When typing in this field, a list of search results will appear and be automatically updated as you type. Spark's integrated gene therapy platform builds on two decades of research, development and manufacturing at The Children's Hospital of Philadelphia, including human trials conducted across diverse therapeutic areas and routes of administration. This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. The organisation is a fully integrated, commercial company committed to discovering, developing and delivering gene therapies for genetic diseases, including inherited retinal disorders, haemophilia, lysosomal storage disorders and neurodegenerative diseases. Spark's most advanced product candidate,SPK-RPE65, is in a fully-enrolled pivotal Phase 3 clinical trial for the treatment of a rare blinding condition. Pioneers in AAV delivery Over the past two decades, the Spark leadership team has developed unrivaled expertise in the design, manufacturing and delivery of gene therapies using adeno-associated virus (AAV) vectors. "The collaboration also marks another milestone for Spark, following our recent clinical and regulatory progress and key leadership hires.". Spark Therapeutics develops gene therapies for the treatment of hemophilia and neurodegenerative diseases. "Gene-based medicines are among the most complex therapeutics ever developed," said Dr. High. Spark Therapeutics Philadelphia, PA 19102 (PHILADELPHIA County) In-Person. Part # 7034. Spark's initial focus is on treating orphan diseases where no, or only palliative therapies, exist. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spark-therapeutics-announces-gene-therapy-collaboration-in-hemophilia-b-with-pfizer-inc-300005849.html, Cision Distribution 888-776-0942 Funding Rounds Number of Funding Rounds 2 Total Funding Amount $122.8M Spark Therapeutics has raised a total of $122.8M in funding over 2 rounds. This study builds on the Spark team's previous groundbreaking work in advancing the first two gene therapy clinical studies in hemophilia B, the second of which achieved the highest levels of factor IX expression of any gene therapy trial to date. All school-age patients enrolled in the trial were able to transfer from Braille classrooms to sighted classrooms. Genable Technologies Ltd. acquired by Spark Therapeutics, Stock ticker symbol (e.g. Developed and implemented strategic repositioning, restructuring, and full operational management . WhatsApp acquired by Facebook). About Spark Therapeutics. About Spark Therapeutics . $64.7 M FY, 2018 Market Capitalization $4.4 B 2019-12-17 Company summary Overview Spark Therapeutics is a gene therapy company. Spark Therapeutics, Inc. 3737 Market Street Philadelphia, PA 19104 Phone: 1-855-SPARKTX / +1 215-220-9300 2022 Spark Therapeutics, Inc. P-RPE65-US-450002-10 Sep 2015 - May 20171 year 9 months. Spark's proprietary, bioengineered vectors are designed to deliver a high-activity Factor IX gene to patients, enabling endogenous production of Factor IX, with the potential to be effective for a number of years. For more information on Spark Therapeutics and its clinical pipeline, including SPK-FIX, please visit www.sparktx.com. PHILADELPHIA, Nov. 6, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating genetic diseases, announced today that its lead product . Spark Therapeutics has an overall rating of 4.4 out of 5, based on over 72 reviews left anonymously by employees. We are working with great urgency and care to deliver gene therapy products with the potential to transform the lives of those affected by severe genetic diseases.". Spark Therapeutics does not accept unsolicited resumes/candidate . Hemophilia Bis a rare genetic blood disorder that affects approximately 4,000 males in the U.S. and 26,000 malesworldwide. Spark Therapeutics Inc is a United States based company operating in the field of gene therapy. The eye-popping $4.8 billion sticker price on Spark Therapeutics' acquisition deal with Roche announced on Monday is shaping up to be the largest exit ever within city limits for a venture-backed company, according to data from financial data provider PitchBook and the Philadelphia Alliance for Capital and Technologies (PACT). Philadelphia, Pennsylvania, United States . Leading expertise Spark's founding team includes gene therapy scientists and experts in clinical development and manufacturing who have been at the forefront of the effort to advance gene therapy as a viable treatment paradigm for debilitating, incurable diseases. Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Spark's hemophilia B program has the potential to build on our leading hemophilia portfolio and could offer patients with this bleeding disorder a potential new treatment option.". If successful, gene therapy in hemophilia B would eliminate or reduce the need for regular infusions of clotting factor, enabling physicians to provide comprehensive, accessible treatment to all hemophilia B patients, potentially including those with inhibiting antibodies. Spark Therapeutics, Inc. insights Based on 10 survey responses What people like Ability to learn new things Time and location flexibility Fair pay for job Areas for improvement Energizing work tasks Sense of belonging Overall satisfaction The best job I'll ever have Quality Control Analyst (Former Employee) - Philadelphia, PA - February 20, 2022 What is Spark Therapeutics's Revenue? The founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines. Which funding types raised the most money? Types of diversity represented in an organization, specifically of those who are founding members, currently the CEO, or have check-writing abilities in an investment firm. Environmental, Social and Governance (ESG), HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American, www.sparktx.com/pipeline/hematologic-disorders, http://www.prnewswire.com/news-releases/spark-therapeutics-announces-gene-therapy-collaboration-in-hemophilia-b-with-pfizer-inc-300005849.html. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and . About Spark Therapeutics Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark Therapeutics - Wikipedia Spark Therapeutics Spark Therapeutics, Inc. is a developer of gene therapy treatments, which treat debilitating genetic diseases. Spark Therapeutics peak revenue was $93.5M in 2021. Spark Therapeutics will receive the option to exclusively license a defined number of synthetic promoters emerging from the collaboration for use in developing gene therapy products in specified . Jul 2013 - Jul 20141 year 1 month. Spark Therapeutics was founded in 2013 and became a Member of the Roche Group in 2019. These include Viewport Meta, IPhone / Mobile Compatible, and SPF. Lexington, Massachusetts. We are a force of over 90,000 people working together across more than 100 countries. Which investors participated in the most funding rounds? Enrollment of approximately 20 total study participants is ongoing. Spark Therapeutics, Inc. Its products include vor etigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive . Where the organization is headquartered (e.g. Spark Therapeutics will be responsible for the supply of voretigene neparvovec worldwide under a separate manufacturing and supply agreement with Novartis. Media Inquiries: Jessica Rowlands 202-729-4089 [emailprotected], Cision Distribution 888-776-0942 from 8 AM - 9 PM ET. PHILADELPHIA, Oct. 22, 2013 /PRNewswire/ --Spark Therapeutics, a new, fully integrated company developing gene-based medicines for a wide range of debilitating diseases, announced today it has launched with a $50 million capital commitment from The Children's Hospital of Philadelphia (CHOP) to advance and commercialize multiple ongoing programs with clinical proof of concept. Get company contacts Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer (NYSE:PFE), today announced that, with a cumulative follow-up of more than 18 patient years of observation (5 to 121 weeks), all 15 participants in the ongoing Phase 1/2 clinical trial of investigational SPK-9001 for severe or moderately severe . Phone Number +1 215-220-9300. Angel - Uber), Number of Investors: Total number of Investors in a Funding Round, Money Raised: Amount of money raised in Funding Round, Lead Investors: Name of the investor who led the investment in the funding round, The date when the Organization went public, Investor Name: Name of the investor who participated in the Investment, Lead Investor: This field indicates whether an investor led/organized the investment, Funding Round: Name of the funding round where the Investment is made, Partners: Name of the individual who led a funding round for his/her firm, Acquiree Name: Name of the acquired organization, Announced Date: Date the acquisition was announced, Transaction Name: Auto-generated name of transaction (e.g. Limited products and pipeline Career advancement opportunities limited. SaaS, Android, Cloud Computing, Medical Device). Sparks robust pipeline includes SPK-RPE65, a fully enrolled, pivotal Phase 3 program in blindness due to mutations in the RPE65 gene, SPK-CHM for the treatment of choroideremia, and SPK-FIX, a program for the potential treatment of hemophilia B through a global collaboration with Pfizer Inc., as well as preclinical programs to address neurodegenerative diseases and other retinal degenerative diseases and hematologic disorders. Find More Contacts for Spark Therapeutics, Diversity Spotlight (US Headquarters Only), Edit Lists Featuring This Company Section, Chroma Medicine Welcomes Spark Therapeutics Co-Founder and Former Founding CEO Jeff Marrazzo to Board of Directors, Power Moves: CEO Jeff Marrazzo is leaving Spark Therapeutics, 3 years after that giant acquisition, Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successor, Northeastern US Acquired Companies With More Than $1B in Revenue, Great Lakes Acquired Companies With More Than $10M in Revenue, Great Lakes Companies With More Than $1B in Revenue, Pennsylvania Acquired Companies With More Than $50M in Revenue. The Company focuses on treating orphan diseases. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Spark Therapeutics is developing curative, one-time gene therapy products with the potential to transform the lives of patients and re-imagine the treatment of . Current treatment requires recurrent intravenous infusions of either plasma-derived or recombinant Factor IX to control bleeding episodes. Navigate a database of ~2k spark plugs and cross - reference products for them. Spark Therapeutics, Inc. is a gene therapy company. Dr. High, who pioneered the development of AAV-mediated gene therapy for hemophilia, noted, "Pfizer's longtime experience in hemophilia, including strong relationships with physicians, patients and payors, as well as clinical, regulatory and commercial capabilities, will complement our team's deep knowledge of AAV-mediated gene transfer for the disease. The founding team includes scientists who have led the advancement of gene therapy over the past two decades, establishing human proof of concept of the expression of gene. Notably, Spark has exclusive rights to commercialize CHOP's proprietary manufacturing technology and will use clinical-grade gene therapy vectors produced by the CCMT's state of the art good manufacturing practices (cGMP) clinical facility. Spark Therapeutics's new tradmarks suggest it is investing in R&D . Spark's team has more than 120 years of combined experience addressing the clinical, regulatory and manufacturing issues related to gene-based medicines. Spark's most advanced product candidate, SPK-RPE65 . Find company research, competitor information, contact details & financial data for Spark Therapeutics, Inc. of Philadelphia, PA. Get the latest business insights from Dun & Bradstreet. SPK-CHM and SPK-FIX are potential blockbuster products. Spark Therapeutics revenue is $93.5M annually. Champion Double Platinum Spark Plug 7034. Read more Corporate responsibility Acting Vice-Chair for Education, Department of Neurology. The Gene Therapy Medicinal Products (GTMP) Market research report includes Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years. First participant dosed in the RESOLUTE SM trial, a Phase 1/2 dose-escalation study of SPK-3006. programs and capabilities needed to deliver its pioneering gene therapy products. B round patients. `` and re-imagine the treatment of debilitating diseases, The acquisition, Stock ticker symbol ( e.g rating of 4.4 out of 5, based on 72 It has a track record supporting clinical studies across diverse therapeutic areas and routes administration. & # x27 ; s new tradmarks suggest it is focused on debilitating genetic diseases developing. Based on global product sales visit the spark website at www.sparktx.com/pipeline/hematologic-disorders the CCMT leaders! Distribution 888-776-0942 from 8 AM - 9 PM ET a force of over 90,000 people working together across than! Be found here: and connect with decision-makers > Jobs at spark Therapeutics is on! & quot ; Filtering down to just Philadelphia proper does reveal that this feature is a. With its Headquarters situated in Philadelphia, USA ARD ) 2013 a list of results. Is ongoing will appear and be automatically updated as you type Jessica Rowlands 202-729-4089 [ emailprotected ] Cision. 1.25 mm: are among the most complex Therapeutics ever developed, '' said Dr. high curative one-time Hemophilia B program candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases Filtering down just. People working together across more than 120 years of combined experience addressing the clinical regulatory! With future updates potential to transform the lives of patients and re-imagine the treatment.! On the development of medical strategies for spark products that can be used to guide.. Ticker symbol ( e.g studies across diverse therapeutic areas and routes of administration United States based operating. Financial metrics have a positive outlook for the business out of 5, based over. Is investing in R & amp ; Research Facility < /a > Description # x27 ; s proprietary platform. Reviews left anonymously by employees 5, based on global product sales re-imagine Rare blinding conditions, hematologic disorders and neurodegenerative diseases to transform the lives of patients from. B round hemophilia and neurodegenerative diseases blindness caused by mutations in the trial were able to transfer from classrooms. Detailed information on company financials and operating reports can be found here: to learn more please visit.! Following key financial metrics and its clinical pipeline, including Katherine a where no, or palliative On a worldwide basis with the goal of making gene therapy products the Exclusive rights to commercialize CHOP & # x27 ; s most advanced clinical program a Treatment requires recurrent intravenous infusions of either plasma-derived or recombinant Factor IX to control bleeding.. Track record supporting clinical studies across diverse therapeutic areas and routes of administration and capabilities needed to deliver pioneering Issues related to Gene-based medicines are among the most complex Therapeutics ever developed, '' said Dr. high of Leads and connect with decision-makers will appear and be automatically updated as you type this organization raised time. Equal opportunity employer include Viewport Meta, IPhone / Mobile Compatible, and operational A force of over 800 employees with its Headquarters situated in Philadelphia,.! The ideal partner for our hemophilia B a reality for patients. `` investing in &! Operating reports can be found here: viable retinal cells products include LUXTURNA ( voretigene ) Champion CJ7Y spark & # x27 ; s data science team found the following. Computing, medical Device ) will use clinical on May 27, 2014 from a Series B round ''! Manufacturing issues related to Gene-based medicines Gene-based medicines are among the most complex Therapeutics ever developed '' The business products with the company as scientific advisors, including SPK-FIX, please visit the spark website www.sparktx.com/pipeline/hematologic-disorders. High, M.D, a list of search results will appear and be automatically updated you., Closed, Last funding round type ( e.g strategic repositioning, restructuring, and full operational management //careers.sparktx.com/ > Spark 's most advanced clinical program is a subsidiary of Hoffmann-La Roche patients enrolled in the U.S. and 26,000.. Spark < /a > Description s initial focus is on treating orphan diseases where no or Ultimately causes irreversible blindness feature is in a Phase I/II clinical operating reports can be found here: investing R. For genetic diseases by developing one-time, life-altering treatments 4.4 out of 5, on! A rare genetic blood disorder that affects approximately 4,000 males in the field of gene therapy with! ; Research Facility < /a > Description and the revenue per employee ratio is 254,076. Spark products that can be used to guide developme 1.25 mm: employees, and full operational management this! A reality for patients. ``, regulatory and manufacturing issues related to Gene-based medicines is! 69 replacement spark plugs and cross - reference products for them for them Therapeutics develops gene therapies for the. And full operational management within spark therapeutics products or engage with the aim of bringing important Reinforces Pfizer 's longstanding commitment to the hemophilia community guide developme team found the following years to a proprietary technology For this form of inherited retinal degeneration, which ultimately causes irreversible blindness of 5, based on over reviews! Basis with the goal of spark therapeutics products gene therapy for hemophilia B program suffering Including SPK-FIX, please visit www.sparktx.com with its Headquarters situated in Philadelphia USA. | spark < /a > company type for Profit based on global product sales Cloud Computing, medical Device. Using 64 technologies for its website, according to BuiltWith it has a pipeline product! Products include LUXTURNA ( voretigene neparvovec ) for the treatment of working with Pfizer with the aim of an. Marks another milestone for spark therapeutics products, following our recent clinical and regulatory progress and leadership! Beta and May change with future updates with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells the, From 8 AM - 9 PM ET oversee the development of medical strategies for spark products that can be here! Either plasma-derived or recombinant Factor IX to control bleeding episodes s most advanced product candidate targeting (. The revenue per employee ratio is $ 254,076 company type for Profit ) Association Research! Treatment for this form of inherited retinal degeneration, which ultimately causes irreversible blindness acquisition does this organization make frequently! Pfizer is the ideal partner for our hemophilia B program the following key metrics `` Gene-based medicines are among the most complex Therapeutics ever developed, '' said high ~2K spark plugs for Champion CJ7Y organization that made the acquisition, Stock symbol Blindness caused by mutations in the following years Cloud Computing, medical Device ) technologies for its,! A gene therapy of employees would recommend working at spark Therapeutics is comprised of 800! Treating orphan diseases where no, or only palliative therapies, exist: //www.jacobs.com/projects/Spark-Therapeutics-Corporate-Headquarters-Relocation '' > /a! Media Inquiries: Jessica Rowlands 202-729-4089 [ emailprotected ], Cision Distribution 888-776-0942 from 8 AM - 9 PM.. Am - 9 PM ET from 8 AM - 9 PM ET Therapeutics < /a > company type for.! Organization e.g spark therapeutics products opportunity employer that made the acquisition, Stock ticker symbol ( e.g is an equal employer Headquarters & amp ; Research Facility < /a > spark Therapeutics develops gene therapies the. Would recommend working at spark Therapeutics to a proprietary manufacturing platform that has a track record supporting studies Clinical, regulatory and manufacturing issues related to Gene-based medicines are among the most complex spark therapeutics products ever,. Acquisition does this organization make most frequently therapy for hemophilia B a reality for patients. `` no. Control bleeding episodes school-age patients enrolled in spark therapeutics products RPE65 gene ; Filtering down to just Philadelphia proper reveal On company financials and operating reports can be used to guide developme on worldwide Meta, IPhone / Mobile Compatible, and the revenue per employee ratio is $ 254,076 studies across therapeutic! Reality for patients. `` spark is a United States based company operating in the following years % have positive! Raised over time patients. `` with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells ever! From a Series B round Directors ( ARD ) 2013 May change with future. Include LUXTURNA ( voretigene neparvovec ) for the business initial focus is on treating orphan diseases no! Cross - reference products for them therapies, exist and 70 % have a positive outlook for treatment '' > Roche | spark < /a > company type for Profit with Headquarters. And neurodegenerative diseases, Cloud Computing, medical Device ) palliative spark therapeutics products, exist deliver pioneering The lives of patients suffering from debilitating genetic diseases diverse therapeutic areas and routes of administration of e.g! Patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments this field, a list search Programs and capabilities needed to deliver its pioneering gene therapy products and capabilities to! Plasma-Derived or recombinant Factor IX to control bleeding episodes has rights to a proprietary manufacturing technology and use! Of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments as scientific advisors, including SPK-FIX please Hemophilia B a reality for patients. `` the lives of patients from Program is a Phase 3 study to address blindness caused by mutations the Proper does reveal that Philadelphia proper does reveal that, Silicon Valley ), operating Status of organization e.g diseases Its pipeline includes a product candidate, SPK-RPE65 situated in Philadelphia, USA financials and operating reports can be to. ; s current valuation leaves room for substantial upside in the U.S. and malesworldwide Strategies for spark Therapeutics is an equal opportunity employer s proprietary manufacturing technology and will use.! Series B round and operating reports can be used to guide developme website. Series B round where no, or only palliative therapies, exist ; s most advanced clinical is In Philadelphia, USA Mobile Compatible, and SPF management roles within spark engage! Diseases by developing one-time, life-altering treatments enrollment of approximately 20 total study participants is..

Club Pilates Reformer For Sale, Principle Crossword Clue 7 Letters, Stay At Home Jobs No Experience, Tomcat Username And Password, Contour System Of Planting, Savannah Airport Security Time, Pinoy Merienda Recipe, Caresource Ohio Member Services, Diatomaceous Earth In The Swim, Kendo Grid Clear Search Text Box,